Synpromics works with UCL

Synpromics Ltd is bringing its technology for creating synthetic promoters into a partnership with a unit of University College London (UCL) in order to help researchers there develop gene therapies for blood-based disorders. The agreement was announced on 25 January.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom